AtriCure (ATRC) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.17
- Estimate
- $0.01
- Surprise
- +1326.2%
- Score today
- 6.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
AtriCure (ATRC) beat the $0.01 estimate with adjusted EPS of $0.17 — a large 1326.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ATRC Hold at 6.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +1326.2% surprise compares with a +581.6% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Supplier: single and limited source third-party vendors
- Analyst target reached - limited upside remaining
- Near 52-week high (4.1% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $60.41
- Stop
- $56.19
The stock trades at 287.7× trailing but 139.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
ATRC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.07B
- P/E (fwd)
- 139.2
- P/E (ttm)
- 287.7
- 52-week range
- $25.36–$63.00
- Off 52-week high
- 4.1%
- RSI (14)
- 61
- Volume vs avg
- 2.16×
- Score today
- 6.2/10